Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | NAAA | Q02083 | 2/20 | 0.58 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.53 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.47 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20810289 | 0.84 | SPHK2 (0.59) | SMN1; SMN2NAAASPHK2SPHK1SMPD1 | |
| SCHEMBL5256832 | 0.83 | SMN1; SMN2 (0.68) | SMN1; SMN2NAAASPHK2SPHK1L3MBTL1 | |
| SCHEMBL5256827 | 0.83 | SMN1; SMN2 (0.68) | SMN1; SMN2NAAASPHK2SPHK1L3MBTL1 | |
| SCHEMBL131829 | 0.82 | SMN1; SMN2 (0.87) | SMN1; SMN2NAAAL3MBTL1LMNA | |
| SCHEMBL6535127 | 0.82 | SMN1; SMN2 (0.87) | SMN1; SMN2NAAAL3MBTL1LMNA | |
| SCHEMBL1854346 | 0.82 | SMN1; SMN2 (0.66) | SMN1; SMN2NAAASPHK2SPHK1L3MBTL1 | |
| SCHEMBL20646968 | 0.81 | SMN1; SMN2 (0.57) | SMN1; SMN2NAAASPHK2SPHK1L3MBTL1 | |
| SCHEMBL20810312 | 0.81 | PPARA (0.56) | SMN1; SMN2NAAASPHK2SPHK1SMPD1 | |
| SCHEMBL15173985 | 0.80 | SPHK2 (0.64) | SMN1; SMN2SPHK2SPHK1NPC1RAB9A | |
| SCHEMBL15174533 | 0.80 | SPHK2 (0.64) | SMN1; SMN2SPHK2SPHK1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8551999-B2 | Heterocyclic compound and pharmaceutical composition thereof | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| EP-2207773-B1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | OTSUKA PHARMA CO LTD (JP) | 2012-07-11 | — | — | EP | disclosed |
| US-20100261720-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-10-14 | — | — | US | disclosed |
| EP-2207773-A2 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | Otsuka Pharmaceutical Co., Ltd. (JP) | 2010-07-21 | — | — | EP | disclosed |
| WO-2009057811-A2 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261720-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | COL1A1, COL2A1, COL14A1 | SMN1; SMN2 3814/4885NAAA 3835/4885SPHK2 4448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.